2022 Announcements

CLINUVEL
Posted by CLINUVEL
February 15, 2022

DNA Repair Communiqué I

This first Communiqué in a series on DNA forms an introductory foundation,...

Read More
CLINUVEL
Posted by CLINUVEL
February 14, 2022

CLINUVEL Expands DNA Repair Program with 2nd DNA Repair Study

CLINUVEL today announced that the first disease-free subjects have received afamelanotide as...

Read More
CLINUVEL
Posted by CLINUVEL
January 31, 2022

Appendix 4C & Activity Report

Melbourne, Australia, 31 January 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL.
Posted by CLINUVEL.
January 28, 2022

CLINUVEL Kommuniqué 1

Happy New Year to all our stakeholders for 2022, a year in...

Read More
CLINUVEL.
Posted by CLINUVEL.
January 27, 2022

CLINUVEL Communiqué 1

Happy New Year to all our stakeholders for 2022, a year in...

Read More
CLINUVEL
Posted by CLINUVEL
January 24, 2022

SCENESSE® continued in Germany

CLINUVEL today announced that it has entered a second agreement with the...

Read More
CLINUVEL
Posted by CLINUVEL
January 19, 2022

Change of Director’s Interest Notice

Melbourne, Australia, 19 January 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
January 19, 2022

Notification of Cessation of Securities

Melbourne, Australia, 19 January 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
January 17, 2022

CLINUVEL completes enrolment in world-first stroke study

CLINUVEL today announced that it has completed enrolment in its world-first study...

Read More
CLINUVEL
Posted by CLINUVEL
January 10, 2022

CLINUVEL’S GROWTH AND EXPANSION - H.C. Wainwright Bioconnect Conference 2022

CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the H.C. Wainwright...

Read More